Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$1.4b

Vor Biopharma Valuation

Is VOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate VOR's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate VOR's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VOR?

Key metric: As VOR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for VOR. This is calculated by dividing VOR's market cap by their current earnings.
What is VOR's PE Ratio?
PE Ratio2.2x
EarningsUS$627.78m
Market CapUS$1.40b

Price to Earnings Ratio vs Peers

How does VOR's PE Ratio compare to its peers?

The above table shows the PE ratio for VOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average7x
ABUS Arbutus Biopharma
5.7x-95.54%US$906.7m
AUPH Aurinia Pharmaceuticals
6.5x-4.79%US$2.1b
RIGL Rigel Pharmaceuticals
2.4x-22.76%US$778.2m
ADMA ADMA Biologics
13.1x20.73%US$2.2b
VOR Vor Biopharma
2.2x-30.06%US$1.4b

Price-To-Earnings vs Peers: VOR is good value based on its Price-To-Earnings Ratio (2.2x) compared to the peer average (7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does VOR's PE Ratio compare vs other companies in the US Biotechs Industry?

16 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.16.4x27.3%
VOR Vor Biopharma
 2.2x-30.06%US$1.40b
RIGL Rigel Pharmaceuticals
2.4x-22.76%US$778.20m
AGEN Agenus
3.3x-66.70%US$315.14m
VOR 2.2xIndustry Avg. 16.4xNo. of Companies16PE01632486480+
16 CompaniesEstimated GrowthMarket Cap
Industry Avg.16.4x27.3%
VOR Vor Biopharma
 2.2x-30.06%US$1.40b
No more companies

Price-To-Earnings vs Industry: VOR is good value based on its Price-To-Earnings Ratio (2.2x) compared to the US Biotechs industry average (16.4x).

Price to Earnings Ratio vs Fair Ratio

What is VOR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VOR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio2.2x
Fair PE Ratio11.1x

Price-To-Earnings vs Fair Ratio: VOR is good value based on its Price-To-Earnings Ratio (2.2x) compared to the estimated Fair Price-To-Earnings Ratio (11.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VOR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$23.59
US$39.00
+65.32%
21.11%US$50.00US$27.00n/a8
Aug ’27US$21.15
US$37.88
+79.08%
26.87%US$50.00US$18.00n/a8
Jul ’27US$18.39
US$37.88
+105.95%
26.87%US$50.00US$18.00n/a8
Jun ’27US$14.57
US$37.88
+159.95%
26.87%US$50.00US$18.00n/a8
May ’27US$13.85
US$37.50
+170.76%
29.15%US$50.00US$15.00n/a8
Apr ’27US$17.39
US$37.63
+116.36%
28.87%US$50.00US$15.00n/a8
Mar ’27US$15.44
US$44.60
+188.86%
17.91%US$55.00US$32.00n/a5
Feb ’27US$13.00
US$44.60
+243.08%
17.91%US$55.00US$32.00n/a5
Jan ’27US$13.08
US$43.25
+230.66%
19.44%US$55.00US$32.00n/a4
Dec ’26US$7.68
US$50.33
+555.38%
26.77%US$64.00US$32.00n/a3
Nov ’26US$24.11
US$45.50
+88.72%
48.26%US$64.00US$8.00n/a4
Oct ’26US$39.26
US$35.75
-8.94%
62.18%US$60.00US$8.00n/a4
Sep ’26US$39.40
US$23.50
-40.36%
92.52%US$60.00US$6.00n/a4
Aug ’26US$42.00
US$23.50
-44.05%
92.52%US$60.00US$6.00US$21.154
Jul ’26US$28.60
US$23.50
-17.83%
92.52%US$60.00US$6.00US$18.394
Jun ’26US$4.00
US$6.33
+58.41%
19.69%US$8.00US$5.00US$14.573
May ’26US$13.22
US$202.86
+1,434.47%
44.54%US$360.00US$100.00US$13.857
Apr ’26US$12.40
US$202.86
+1,535.94%
44.54%US$360.00US$100.00US$17.397
Mar ’26US$21.60
US$235.71
+991.27%
38.87%US$360.00US$120.00US$15.447
Feb ’26US$28.40
US$235.71
+729.98%
38.87%US$360.00US$120.00US$13.007
Jan ’26US$22.20
US$235.71
+961.78%
38.87%US$360.00US$120.00US$13.087
Dec ’25US$16.64
US$263.91
+1,485.83%
24.94%US$360.00US$160.00US$7.687
Nov ’25US$16.10
US$263.75
+1,538.61%
41.62%US$440.00US$60.00US$24.118
Oct ’25US$12.76
US$263.75
+1,967.01%
41.62%US$440.00US$60.00US$39.268
Sep ’25US$17.48
US$263.75
+1,408.52%
41.62%US$440.00US$60.00US$39.408
Aug ’25US$18.80
US$281.25
+1,396.01%
29.88%US$440.00US$200.00US$42.008
US$39
Fair Value
39.5% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/12 05:14
End of Day Share Price 2026/08/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vor Biopharma Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Justin WalshB. Riley Securities, Inc.